EA200870237A1 - Последовательности пептидов и композиции - Google Patents

Последовательности пептидов и композиции

Info

Publication number
EA200870237A1
EA200870237A1 EA200870237A EA200870237A EA200870237A1 EA 200870237 A1 EA200870237 A1 EA 200870237A1 EA 200870237 A EA200870237 A EA 200870237A EA 200870237 A EA200870237 A EA 200870237A EA 200870237 A1 EA200870237 A1 EA 200870237A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sequence
polypeptide
peptides
compositions
epitope
Prior art date
Application number
EA200870237A
Other languages
English (en)
Other versions
EA017387B1 (ru
Inventor
Грегори Алан Столофф
Уилсон Ромеро Капаррос-Вандерлей
Original Assignee
Пептселл Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38109631&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200870237(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0602416A external-priority patent/GB0602416D0/en
Application filed by Пептселл Лимитед filed Critical Пептселл Лимитед
Publication of EA200870237A1 publication Critical patent/EA200870237A1/ru
Publication of EA017387B1 publication Critical patent/EA017387B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271—Demonstrated in vivo effect

Abstract

В настоящем изобретении предоставлен полипептид, состоящий из не более чем 100 аминокислот, который содержит одну или более последовательностей, которые по меньшей мере на 60% гомологичны с любой из SEQ ID NO: 1-6, или содержит два или более эпитопов из 7 или более аминокислот, каждый эпитоп по меньшей мере на 60% гомологичен субпоследовательности любой из SEQ ID NO:1-6, которая имеет такую же длину, как и эпитоп:где полипептид является иммуногенным для позвоночного, экспрессирующего аллель главного комплекса гистосовместимости (МНС), и где полипептид не является полным белком вируса гриппа.
EA200870237A 2006-02-07 2007-02-05 Последовательности пептидов и композиции EA017387B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0602416A GB0602416D0 (en) 2006-02-07 2006-02-07 Peptide sequences and compositions
GBGB0613977.8A GB0613977D0 (en) 2006-02-07 2006-07-13 Peptide sequences and compositions
PCT/GB2007/000383 WO2007091030A2 (en) 2006-02-07 2007-02-05 Peptide sequences and compositions

Publications (2)

Publication Number Publication Date
EA200870237A1 true EA200870237A1 (ru) 2009-06-30
EA017387B1 EA017387B1 (ru) 2012-12-28

Family

ID=38109631

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870237A EA017387B1 (ru) 2006-02-07 2007-02-05 Последовательности пептидов и композиции

Country Status (23)

Country Link
US (10) US8475802B2 (ru)
EP (6) EP3263589B1 (ru)
JP (1) JP5603551B2 (ru)
KR (1) KR20080100441A (ru)
CN (3) CN101395176B (ru)
AP (1) AP2646A (ru)
AT (1) ATE534660T1 (ru)
AU (1) AU2007213562A1 (ru)
BR (1) BRPI0707543B8 (ru)
CA (1) CA2641602A1 (ru)
DK (4) DK2383285T3 (ru)
EA (1) EA017387B1 (ru)
ES (4) ES2635590T3 (ru)
GB (1) GB0613977D0 (ru)
HK (1) HK1249115A1 (ru)
IL (2) IL193232A (ru)
MX (1) MX2008010113A (ru)
NO (1) NO20083416L (ru)
NZ (1) NZ570553A (ru)
PL (4) PL1991563T3 (ru)
PT (1) PT1991563E (ru)
SG (1) SG169392A1 (ru)
WO (1) WO2007091030A2 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0716992D0 (en) * 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
ES2539818T3 (es) 2007-08-02 2015-07-06 Biondvax Pharmaceuticals Ltd. Vacunas contra la gripe multiepitópicas multiméricas
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
EP2772267B1 (en) 2007-08-27 2016-04-27 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
CA2861667C (en) 2007-10-01 2017-06-13 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system and methods of use
GB0719526D0 (en) 2007-10-05 2007-11-14 Isis Innovation Compositions and methods
EP2072529A1 (en) * 2007-12-21 2009-06-24 basisnote AG MHC rapid assay used for the customization of odours
FR2962739B1 (fr) * 2010-07-13 2014-01-31 Univ Claude Bernard Lyon Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza
AU2011360572B2 (en) 2011-02-22 2017-03-02 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2013093514A2 (en) * 2011-12-23 2013-06-27 Retroscreen Virology Ltd Vaccines - peptides
CA2863083C (en) 2012-01-26 2023-09-19 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
EP3231441A4 (en) * 2014-12-10 2018-10-31 Vaxsia Biomedical Inc. Novel protein structure produced by effective antibody used for immunization
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
CN106310214A (zh) * 2015-06-30 2017-01-11 中国科学院上海巴斯德研究所 流感病毒蛋白与宿主蛋白cpsf30的相互作用在抑制癌细胞增殖中的应用
JP2019064924A (ja) * 2016-02-24 2019-04-25 Ａｇｃ株式会社 インフルエンザワクチン
KR101888751B1 (ko) * 2016-09-22 2018-09-21 이화여자대학교 산학협력단 인플루엔자 b 백신
BR112019013402A2 (pt) 2016-12-28 2020-03-03 Invvax, Inc. Vacinas de influenza
CA3086456A1 (en) * 2017-12-21 2019-06-27 Kirin Holdings Kabushiki Kaisha Cross-immunizing antigen vaccine and method for preparation thereof
CN116134137A (zh) * 2020-07-21 2023-05-16 复尔健有限公司 流感病毒骨架

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981782A (en) 1987-05-14 1991-01-01 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use
US5741493A (en) * 1991-01-24 1998-04-21 Pasteur Merieux Serums Et Vaccins Vaccine composition against influenza, with synergic effects, containing influenza virus core as an additive
IL101639A0 (en) * 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
CA2141960A1 (en) * 1992-08-07 1994-02-17 Ralph T. Kubo Hla binding peptides and their uses
US20040087521A1 (en) * 1993-03-18 2004-05-06 Merck & Co., Inc. Nucleic acid pharmaceuticals-influenza matrix
IL109664A0 (en) 1993-05-18 1994-08-26 Rijksuniversiteit Peptides of human influenza virus for use in human t cell response inducing compositions
US6939546B2 (en) 1993-05-21 2005-09-06 The United States Of America As Represented By The Secretary Of The Army Model for testing immunogenicity of peptides
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
AU3727895A (en) 1994-09-30 1996-04-26 St. Jude Children's Research Hospital Nucleic acid encoding mutant matrix proteins useful for attenuation or enhancement of influenza a virus
US7269219B1 (en) * 1997-02-14 2007-09-11 At&T Corp. Non-linear quantizer for video coding
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
JP2001151698A (ja) * 1999-09-10 2001-06-05 Nichiko Pharmaceutical Co Ltd インフルエンザワクチン
AU2002223398A1 (en) 2000-08-10 2002-04-08 Tsinghua University A vaccine for influenza virus and its preparation
KR100927517B1 (ko) * 2000-09-25 2009-11-17 폴리문 사이언티픽 임무노이비오로기쉐 포르슝 게엠베하 생균 백신
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US20050013826A1 (en) * 2002-12-20 2005-01-20 Shneider Alexander M. Vaccine compositions and methods
EP2481819A1 (en) * 2003-02-25 2012-08-01 MedImmune Vaccines, Inc. Cross flow filtration in the production of stabilized influenza vaccine compositions
AU2004220549B2 (en) * 2003-03-07 2007-07-05 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Influenza virus vaccine
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
DE102004052026B4 (de) * 2003-11-07 2015-08-27 Totankako Co., Ltd. Kollektor
FR2863758B1 (fr) * 2003-12-11 2006-07-14 Centre Nat Rech Scient Cellule de commande electronique pour diode electroluminescente organique d'afficheur a matrice active, procedes de fonctionnement et afficheur
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
EP1766094A4 (en) * 2004-05-18 2009-11-25 Vical Inc INFLUENZA VIRUS VACCINE COMPOSITION AND METHODS OF USE
JP2008536526A (ja) * 2005-04-21 2008-09-11 ユニバーシティー オブ フロリダ リサーチ ファウンデイション インコーポレイテッド イヌにおける呼吸器疾患管理のための材料および方法
US20070116717A1 (en) 2005-08-01 2007-05-24 Shneider Alexander M Influenza vaccine compositions and methods
JP5198290B2 (ja) 2006-02-02 2013-05-15 グローブイミューン，インコーポレイテッド 免疫反応を誘発する酵母ベースワクチン
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions

Also Published As

Publication number Publication date
US8475802B2 (en) 2013-07-02
BRPI0707543B1 (pt) 2020-11-24
AP2646A (en) 2013-04-17
CN101395176A (zh) 2009-03-25
EP2383284B1 (en) 2016-08-24
CN102382179B (zh) 2014-01-22
BRPI0707543B8 (pt) 2021-05-25
US20180185470A1 (en) 2018-07-05
US20170028053A1 (en) 2017-02-02
US20120219575A1 (en) 2012-08-30
EP3263589A2 (en) 2018-01-03
IL251867A0 (en) 2017-06-29
AU2007213562A2 (en) 2008-11-20
US20190201519A1 (en) 2019-07-04
US10765734B2 (en) 2020-09-08
EP1991563B1 (en) 2011-11-23
ATE534660T1 (de) 2011-12-15
WO2007091030A3 (en) 2007-11-08
EA017387B1 (ru) 2012-12-28
SG169392A1 (en) 2011-03-30
CN102382179A (zh) 2012-03-21
HK1249115A1 (zh) 2018-10-26
EP2383285A2 (en) 2011-11-02
US8444995B2 (en) 2013-05-21
MX2008010113A (es) 2009-01-19
US9889191B2 (en) 2018-02-13
IL193232A0 (en) 2009-02-11
DK2383285T3 (en) 2017-08-28
EP2383284A2 (en) 2011-11-02
EP3263589B1 (en) 2020-03-25
EP2383285B1 (en) 2017-07-12
NZ570553A (en) 2012-08-31
JP2009526028A (ja) 2009-07-16
BRPI0707543A2 (pt) 2011-05-03
KR20080100441A (ko) 2008-11-18
WO2007091030A2 (en) 2007-08-16
PL2383285T3 (pl) 2017-11-30
CA2641602A1 (en) 2007-08-16
ES2635590T3 (es) 2017-10-04
US9446116B2 (en) 2016-09-20
IL193232A (en) 2017-05-29
CN102807608B (zh) 2015-01-21
US20180147277A1 (en) 2018-05-31
EP3320918A2 (en) 2018-05-16
US20190365883A1 (en) 2019-12-05
AP2008004571A0 (en) 2008-08-31
EP3620463A1 (en) 2020-03-11
ES2374841T3 (es) 2012-02-22
EP3263589A3 (en) 2018-02-14
IL251867B (en) 2018-06-28
GB0613977D0 (en) 2006-08-23
US10335480B2 (en) 2019-07-02
NO20083416L (no) 2008-11-07
AU2007213562A1 (en) 2007-08-16
EP3320918A3 (en) 2018-08-01
DK3263589T5 (da) 2020-05-25
US11439702B2 (en) 2022-09-13
CN101395176B (zh) 2013-02-06
US10279032B2 (en) 2019-05-07
CN102807608A (zh) 2012-12-05
US20230233660A1 (en) 2023-07-27
ES2790730T3 (es) 2020-10-29
DK2383284T3 (en) 2016-12-12
ES2611034T3 (es) 2017-05-04
EP2383285A3 (en) 2012-05-16
PT1991563E (pt) 2011-12-29
JP5603551B2 (ja) 2014-10-08
US20200397889A1 (en) 2020-12-24
PL3263589T3 (pl) 2020-07-13
EP1991563A2 (en) 2008-11-19
DK3263589T3 (da) 2020-05-11
US20100047275A1 (en) 2010-02-25
EP2383284A3 (en) 2012-05-30
PL2383284T3 (pl) 2017-07-31
PL1991563T3 (pl) 2012-02-29
US20130243804A1 (en) 2013-09-19
DK1991563T3 (da) 2012-01-23

Similar Documents

Publication Publication Date Title
EA200870237A1 (ru) Последовательности пептидов и композиции
ES2563646T3 (es) Composiciones y métodos relacionados con variantes de la proteína A (SpA)
CY1119265T1 (el) Κατασκευες νανοσωματων τρισθενους αντι ανθρωπινου αναπνευστικου συγκυτιακου ιου (hrsv) για την προληψη και/ή θεραπεια λοιμωξεων της αναπνευστικης οδου
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
EA201000207A1 (ru) Новые иммуногенные эпитопы для иммунотерапии
EA200901060A1 (ru) Новый способ и композиции
AR064642A1 (es) Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
EP3533461A3 (en) Prame derived peptides and immunogenic compositions comprising these
EA201100071A1 (ru) Новые композиции и способы
EA201100072A1 (ru) Новые композиции и способы
DK1904529T3 (da) Anvendelse af Stefin A som et scaffoldprotein
MX2011007963A (es) Peptidos neil3 y vacunas que incluyen los mismos.
ATE453663T1 (de) Zusammensetzungen von für pathogene stämme spezifischen polypeptiden und deren verwendung als impfstoffe und in der immuntherapie
NZ594268A (en) Grass peptides for vaccine
TR201902131T4 (tr) Enfeksiyöz bronşit virüsünün (IBV) doku tropizmini uzatan mutant diken proteini.
ES2572367T3 (es) Péptidos con epítopos de la MELK y vacunas que los contienen
DE60323634D1 (de) Nichtimmunsuppressive immunogene oder vakzinzusammensetzung enthaltend ein mutiertes e7-protein vom humanen papilloma-virus hpv-16
EA201390811A1 (ru) Пептиды tomm34 и содержащие их вакцины
BR112017019241A2 (pt) análogo peptídico, composição, método para induzir uma resposta imune contra uma infecção, kit, composto e uso de um análogo peptídico
UA97800C2 (ru) Пептидные последовательности и композиции
ATE387629T1 (de) Gemeinsame epitope von antigenen aus einer multigen-familie
MX2011008917A (es) Peptidos vangl1 y vacunas que incluyen los mismos.
EP3556857A3 (en) Cdc45l peptides and vaccines including the same
EA201171430A1 (ru) Пептиды

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM